August 7, 2020Journal of Affective Disorders201 citationsOpen Access
Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
The extent of clinical benefit reported by patients and clinicians following TMS in routine practice compares favorably with alternative interventions for treatment-resistant depression. Strong efficacy and the low side effect and medical risk profile suggest that TMS be evaluated as a first-line treatment for MDD. The findings derive from the largest registry of clinical outcomes in MDD for any treatment.
Cite This Study
Sackeïm et al. (2020) studied this question.